Medical Data Vision Co., Ltd.
Medical Data Vision Co., Ltd. (3902.T) Stock Competitors & Peer Comparison
See (3902.T) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 3902.T | ¥516.00 | -0.19% | 19.5B | -24.79 | -¥20.73 | +1.26% |
| 2413.T | ¥1,882.00 | -0.63% | 1.3T | 31.78 | ¥59.66 | +1.11% |
| 4483.T | ¥3,909.00 | -0.89% | 255.8B | 44.28 | ¥88.35 | +0.41% |
| 2175.T | ¥1,554.00 | +3.02% | 131.1B | 21.76 | ¥70.90 | +1.85% |
| 4480.T | ¥3,135.00 | +1.46% | 96.7B | 43.60 | ¥69.04 | N/A |
| 3733.T | ¥13,340.00 | -1.11% | 69.8B | 14.86 | ¥897.75 | +0.97% |
| 9438.T | ¥908.00 | -2.16% | 50.6B | 19.72 | ¥46.40 | +1.86% |
| 4820.T | ¥725.00 | -0.28% | 50.3B | 17.01 | ¥42.75 | +5.91% |
| 6078.T | ¥1,707.00 | -0.35% | 45.3B | 57.64 | ¥29.46 | +1.53% |
| 5592.T | ¥3,170.00 | -0.63% | 35.6B | 17.54 | ¥180.72 | +0.85% |
Stock Comparison
3902.T vs 2413.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 2413.T has a market cap of 1.3T. Regarding current trading prices, 3902.T is priced at ¥516.00, while 2413.T trades at ¥1,882.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 2413.T's P/E ratio is 31.78. In terms of profitability, 3902.T's ROE is -0.22%, compared to 2413.T's ROE of +0.11%. Regarding short-term risk, 3902.T is more volatile compared to 2413.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 2413.T's competition here
3902.T vs 4483.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4483.T has a market cap of 255.8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4483.T trades at ¥3,909.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4483.T's P/E ratio is 44.28. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4483.T's ROE of +0.10%. Regarding short-term risk, 3902.T is more volatile compared to 4483.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 4483.T's competition here
3902.T vs 2175.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 2175.T has a market cap of 131.1B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 2175.T trades at ¥1,554.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 2175.T's P/E ratio is 21.76. In terms of profitability, 3902.T's ROE is -0.22%, compared to 2175.T's ROE of +0.13%. Regarding short-term risk, 3902.T is more volatile compared to 2175.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 2175.T's competition here
3902.T vs 4480.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4480.T has a market cap of 96.7B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4480.T trades at ¥3,135.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4480.T's P/E ratio is 43.60. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4480.T's ROE of +0.12%. Regarding short-term risk, 3902.T is less volatile compared to 4480.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4480.T's competition here
3902.T vs 3733.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 3733.T has a market cap of 69.8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 3733.T trades at ¥13,340.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 3733.T's P/E ratio is 14.86. In terms of profitability, 3902.T's ROE is -0.22%, compared to 3733.T's ROE of +0.14%. Regarding short-term risk, 3902.T is more volatile compared to 3733.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 3733.T's competition here
3902.T vs 9438.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 9438.T has a market cap of 50.6B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 9438.T trades at ¥908.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 9438.T's P/E ratio is 19.72. In terms of profitability, 3902.T's ROE is -0.22%, compared to 9438.T's ROE of +0.16%. Regarding short-term risk, 3902.T is more volatile compared to 9438.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 9438.T's competition here
3902.T vs 4820.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4820.T has a market cap of 50.3B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4820.T trades at ¥725.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4820.T's P/E ratio is 17.01. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4820.T's ROE of +0.10%. Regarding short-term risk, 3902.T is more volatile compared to 4820.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 4820.T's competition here
3902.T vs 6078.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 6078.T has a market cap of 45.3B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 6078.T trades at ¥1,707.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 6078.T's P/E ratio is 57.64. In terms of profitability, 3902.T's ROE is -0.22%, compared to 6078.T's ROE of +0.12%. Regarding short-term risk, 3902.T is more volatile compared to 6078.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 6078.T's competition here
3902.T vs 5592.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 5592.T has a market cap of 35.6B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 5592.T trades at ¥3,170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 5592.T's P/E ratio is 17.54. In terms of profitability, 3902.T's ROE is -0.22%, compared to 5592.T's ROE of +0.27%. Regarding short-term risk, 3902.T is more volatile compared to 5592.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 5592.T's competition here
3902.T vs 2150.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 2150.T has a market cap of 32.3B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 2150.T trades at ¥735.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 2150.T's P/E ratio is 26.18. In terms of profitability, 3902.T's ROE is -0.22%, compared to 2150.T's ROE of +0.11%. Regarding short-term risk, 3902.T is less volatile compared to 2150.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2150.T's competition here
3902.T vs 3939.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 3939.T has a market cap of 21.2B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 3939.T trades at ¥443.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 3939.T's P/E ratio is 21.63. In terms of profitability, 3902.T's ROE is -0.22%, compared to 3939.T's ROE of +0.26%. Regarding short-term risk, 3902.T is more volatile compared to 3939.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 3939.T's competition here
3902.T vs 3649.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 3649.T has a market cap of 19.3B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 3649.T trades at ¥758.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 3649.T's P/E ratio is 16.59. In terms of profitability, 3902.T's ROE is -0.22%, compared to 3649.T's ROE of +0.20%. Regarding short-term risk, 3902.T is more volatile compared to 3649.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 3649.T's competition here
3902.T vs 5585.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 5585.T has a market cap of 15.8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 5585.T trades at ¥2,184.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 5585.T's P/E ratio is 58.47. In terms of profitability, 3902.T's ROE is -0.22%, compared to 5585.T's ROE of +0.11%. Regarding short-term risk, 3902.T is more volatile compared to 5585.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 5585.T's competition here
3902.T vs 6095.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 6095.T has a market cap of 15.2B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 6095.T trades at ¥698.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 6095.T's P/E ratio is 8.87. In terms of profitability, 3902.T's ROE is -0.22%, compared to 6095.T's ROE of +0.18%. Regarding short-term risk, 3902.T is more volatile compared to 6095.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 6095.T's competition here
3902.T vs 4263.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4263.T has a market cap of 13.8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4263.T trades at ¥843.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4263.T's P/E ratio is -23.71. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4263.T's ROE of -0.06%. Regarding short-term risk, 3902.T is less volatile compared to 4263.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4263.T's competition here
3902.T vs 9341.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 9341.T has a market cap of 12.3B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 9341.T trades at ¥717.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 9341.T's P/E ratio is 8.98. In terms of profitability, 3902.T's ROE is -0.22%, compared to 9341.T's ROE of +0.20%. Regarding short-term risk, 3902.T is more volatile compared to 9341.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 9341.T's competition here
3902.T vs 4320.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4320.T has a market cap of 11.5B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4320.T trades at ¥732.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4320.T's P/E ratio is 23.33. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4320.T's ROE of +0.07%. Regarding short-term risk, 3902.T is less volatile compared to 4320.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 4320.T's competition here
3902.T vs 2934.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 2934.T has a market cap of 8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 2934.T trades at ¥1,590.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 2934.T's P/E ratio is 89.54. In terms of profitability, 3902.T's ROE is -0.22%, compared to 2934.T's ROE of -1.32%. Regarding short-term risk, 3902.T is less volatile compared to 2934.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3902.T.Check 2934.T's competition here
3902.T vs 3671.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 3671.T has a market cap of 7.7B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 3671.T trades at ¥321.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 3671.T's P/E ratio is 16.00. In terms of profitability, 3902.T's ROE is -0.22%, compared to 3671.T's ROE of +0.19%. Regarding short-term risk, 3902.T is more volatile compared to 3671.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 3671.T's competition here
3902.T vs 3628.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 3628.T has a market cap of 7.5B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 3628.T trades at ¥585.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 3628.T's P/E ratio is -2.30. In terms of profitability, 3902.T's ROE is -0.22%, compared to 3628.T's ROE of -1.24%. Regarding short-term risk, 3902.T is more volatile compared to 3628.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 3628.T's competition here
3902.T vs 9218.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 9218.T has a market cap of 7B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 9218.T trades at ¥673.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 9218.T's P/E ratio is -230.14. In terms of profitability, 3902.T's ROE is -0.22%, compared to 9218.T's ROE of +0.26%. Regarding short-term risk, 3902.T is more volatile compared to 9218.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 9218.T's competition here
3902.T vs 4172.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4172.T has a market cap of 5B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4172.T trades at ¥2,285.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4172.T's P/E ratio is 12.18. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4172.T's ROE of +0.10%. Regarding short-term risk, 3902.T is more volatile compared to 4172.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 4172.T's competition here
3902.T vs 6034.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 6034.T has a market cap of 3.9B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 6034.T trades at ¥700.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 6034.T's P/E ratio is -12.23. In terms of profitability, 3902.T's ROE is -0.22%, compared to 6034.T's ROE of -0.08%. Regarding short-term risk, 3902.T is more volatile compared to 6034.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 6034.T's competition here
3902.T vs 6545.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 6545.T has a market cap of 3.8B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 6545.T trades at ¥694.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 6545.T's P/E ratio is 14.83. In terms of profitability, 3902.T's ROE is -0.22%, compared to 6545.T's ROE of +0.17%. Regarding short-term risk, 3902.T is more volatile compared to 6545.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 6545.T's competition here
3902.T vs 4438.T Comparison July 2025
3902.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3902.T stands at 19.5B. In comparison, 4438.T has a market cap of 2.9B. Regarding current trading prices, 3902.T is priced at ¥516.00, while 4438.T trades at ¥356.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3902.T currently has a P/E ratio of -24.79, whereas 4438.T's P/E ratio is -3.61. In terms of profitability, 3902.T's ROE is -0.22%, compared to 4438.T's ROE of -0.88%. Regarding short-term risk, 3902.T is more volatile compared to 4438.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3902.T.Check 4438.T's competition here